In cancers driven by mutant oncogenes, such as KIT or PDGFRA mutant gastrointestinal stromal tumours8,9 and EGFR or EML4-ALK mutant lung cancers10–12, sequential treatments with up to fourth-line kinase inhibitor therapy have achieved long-term disease control and improved patient outcomes. The gene discussed is ALK; the disease is cancer.